Related Experiment Video

Updated: Sep 25, 2025

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
03:22

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE

Published on: March 1, 2024

549

New evidence in severe pneumonia: meropenem-vaborbactam

M Forteza Guillot, M Martín Cerezuela, P Ramírez1

  • 1Paula Ramírez, Servicio de Medicina Intensiva, Hospital Universitario y Politécnico la Fe, Valencia, Spain. paula.ramirez.galleymore@gmail.com.

Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia
|April 30, 2022
PubMed

Insights

Meropenem-vaborbactam offers a potent treatment against carbapenemase-resistant Enterobacteriaceae (CRE), specifically KPC-producing bacteria. This antibiotic demonstrates strong clinical and microbiological efficacy with favorable pharmacokinetics and safety, suggesting durable treatment outcomes.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pharmacology

Background:

  • Antibiotic resistance, particularly carbapenemase production, poses a significant global health threat.
  • Carbapenemase KPC is a challenging resistance mechanism with limited therapeutic choices.
  • Emerging bacterial resistance necessitates novel and effective treatment strategies.

Purpose of the Study:

  • To evaluate the efficacy of meropenem-vaborbactam against carbapenemase-producing KPC bacteria.
  • To assess the clinical and microbiological performance of meropenem-vaborbactam.
  • To determine the pharmacokinetic profile and safety of meropenem-vaborbactam.

Main Methods:

  • Clinical and microbiological data analysis.
  • Pharmacokinetic studies, including lung tissue penetration.
  • Safety and tolerability assessments.

Main Results:

  • Meropenem-vaborbactam demonstrated significant clinical and microbiological efficacy against KPC-producing bacteria.
  • The drug exhibits favorable pharmacokinetic properties, including good penetration into lung tissue.
  • A favorable safety profile was observed, with no significant adverse events reported.

Conclusions:

  • Meropenem-vaborbactam is an excellent therapeutic option for infections caused by carbapenemase KPC.
  • Its pharmacokinetic and safety profile supports its use in diverse patient populations.
  • The apparent absence of resistance development during treatment suggests sustained long-term efficacy.

More Related Videos

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis07:16

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Published on: September 20, 2024

1.2K
Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method12:03

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

26.6K

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
466
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
476
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
198
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
60
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
216
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
737